Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

Healthcare providers often recommend non-steroidal anti-inflammatory drugs (NSAIDs), such as Aleve (naproxen ... The most common cause of peripheral neuropathy is diabetes. Treatment for this ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

The nationwide recall of more than 7000 bottles of duloxetine delayed-release capsules is due to unacceptable levels of a ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

On Wednesday, Sonnet’s stock saw a dramatic rise, making it one of the most talked-about biotech stocks of the day. This uptick comes in the wake of a key announcement from the company: the issuance ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Researchers found that neuromuscular training significantly reduces the incidence and severity of chemotherapy-induced peripheral neuropathy, improving patient quality of life and treatment outcomes.

manufacture and commercialise the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy in India. According to a press statement, “SON-080” is Sonnet’s proprietary ...